SynapseBio uses Machine Learning
and EEG to Improve Detection and Treatment
of Dementia and Other Neuropsychiatric Disorders
SynapseBio is a venture backed Digital Health company founded within AlleyCorp focused on utilizing statistical and machine learning models to assess EEG and other biophysical data for the purpose of improving the detection and treatment of dementia and other Neuropsychiatric disorders.
Current tools to diagnose, treat or predict dementia are
Overly qualitative
Costly and not actionable
Invasive or unvalidated
Advanced statistical analysis and machine learning technology unlocks valuable information hidden within EEG data, including
Real time measurement of brain activity
Ubiquitous, low cost, non-invasive
Patient centric administration bench to bedside
What How We Do
Over the past several years, SynapseBio has developed and refined a domain specific process and algorithm trained to clean and standardize EEG data and generate ML features which has demonstrated efficacy in advanced disease detection across multiple Neuropsychiatric disorders
Clean
Validated algorithm that has been proven to provide a clear signal
Accurate and transparent
Generation of EEG features in a quantitative structure for ML analysis and proprietary ML algorithms generate signal precision
Repeatable
Coding of signal for repeatable digital biomarker use by payers / providers and pharma
Our Digital Biomarkers
SynapseBio is focusing first on 3 digital biomarkers for dementia
Diagnostic
Predictive
Therapy Monitoring
contact@synapsebioai.com
Phone
+1 (212) 634-4062